It has been reported that in allogeneic stem cell transplantation, the mannan-binding lectin (MBL) status of the donor has prognostic value for the recipient. Two MBL-deficient patients, with coexisting haematological malignancy, were identified who were treated with bone marrow from donors with normal MBL concentrations. Although both patients engrafted successfully and remain in complete remission, neither seroconverted to the MBL sufficiency status of his donor over a follow-up period exceeding 2 years. This does not support the concept of MBL replacement by stem cell therapy, and does not provide an explanation for high MBL concentrations in stem cell donors protecting recipients from post transplant infections.
tin; stem cells; stem cell transplantation; innate immunity Mannan-binding lectin (MBL) is a plasma protein synthesized by the liver and circulated in the blood. It is thought to play an important role in innate immunity, by recognizing carbohydrate-based pathogen-associated molecular patterns on microbial surfaces and activating complement using MBL-associated serine protease-2 (the lectin pathway of complement activation) and thereby opsonizing microorganisms for phagocytosis. The capacity to activate complement in this way is a function of multimer formation from basic triplet subunits and is genetically determined. The minority in the population with low circulating oligomeric MBL concentrations are deemed MBL deficient or insufficient, and seem to be more vulnerable to infections generally. [1] [2] [3] This consideration has prompted the suggestion that in some clinical contexts, MBL replacement therapy (in the form of a plasma-derived or recombinant protein) might be beneficial. 4, 5 A study of 97 allogeneic stem cell transplant donorrecipient pairs demonstrated an increased risk of post transplant infection if either the recipients or their donors had genetically defined MBL insufficiency. 6, 7 The finding that patients with mbl-2 gene mutations conferring low plasma MBL concentrations were more susceptible, and conversely those with high MBL-producing haplotypes less susceptible, to major infections, was unsurprising and might have been expected. However, a similar and even stronger association with mutant alleles in the donor was surprising, and could only be explained if some of the cells in the stem cell donation could synthesize MBL or could differentiate into cells that could synthesize MBL. At the time, extrahepatic synthesis of human MBL had not been reported.
We have since provided evidence that human leucocytes (monocytes and dendritic cells) can indeed synthesize MBL and express it on the cell surface. 8 These observations therefore support the theoretical possibility that donorderived monocytes (for example) could differentiate into MBL-secreting tissue macrophages in vivo.
We have also investigated the influence of MBL in patients rendered neutropenic by chemotherapy, many of whom received autologous or allogeneic stem cell transplants. 9 From that previous study, six patients with barely detectable serum MBL who received an allogeneic stem cell transplant were identified. Therefore, by taking blood samples from the donors, it would be possible to establish if any of them had MBL concentrations significantly higher than the corresponding patients and, if so, by taking a further blood sample from the patients (recipients), it should be possible to establish if any patient seroconverted to a higher MBL concentration as a result of the transplant.
Cell therapy as a means of delivering MBL to MBLdeficient subjects is potentially advantageous as it should effect a permanent cure (in sharp contrast to passive infusion of the plasma-derived MBL formulation which has a biological half-life of only 3 days 4 ). In the specific instance of immunosuppressed transplant patients, it could be important to establish the MBL status of donors and recipients to determine whether MBL should be administered in some form as prophylaxis against life-threatening infections. Indeed, it is conceivable that MBL status could contribute in the future to donor selection, particularly for unrelated donor transplants. It is therefore important to establish whether MBL sufficiency can be achieved by cellular therapy in vivo.
Patients and methods
The patients studied were selected from a larger group of patients who experienced iatrogenic neutropenia from treatment of haematological malignancies described in detail elsewhere. 9 From the small subset (21/128) of those patients who were treated with allogeneic haemopoietic stem cell transplantation, six had MBL concentrations p100 ng/ml around the time of neutropenia. One of the patients had since died and another died while ethical permission was being requested to approach the donors. This investigation therefore involved four patients and their donors; three pairs representing related (sibling) transplants, the other representing unrelated donor transplants. Donors and recipients provided blood samples obtained with informed consent, and the project was approved by the North Glasgow Research Ethics Committee.
MBL in serum was determined by enzyme-linked immunosorbent assay. 10 The crucial steps in this procedure are the capture of MBL by solid-phase mannan and its detection using a murine monoclonal anti-MBL antibody (clone 131-1). Although MBL deficiency and MBL insufficiency are imprecise terms, the cutoff values for which are to some extent arbitrary, we consider p100 ng/ ml to constitute deficiency and p600 ng/ml to constitute insufficiency. The former range includes about 10% of the healthy population and virtually all subjects who are homozygotes/compound heterozygotes for mutant structural alleles; the latter includes almost a third of the healthy population and crudely distinguishes homozygotes for the normal (wild-type) structural gene from wild-type/mutant heterozygotes.
Results
Of 21 patients who had received chemotherapy as conditioning for allogeneic stem cell transplants, none demonstrated a significant increase in serum MBL between pre-transplant sampling and the time of neutrophil recovery ( 9 and Table 1 ). This finding does not support the concept of MBL transfer from stem cells, but cannot be confidently interpreted in patients with relatively high MBL concentrations pre-transplant or without knowledge of donor MBL levels.
Six patients were found to have very low serum MBL (p100 ng/ml) before transplantation. Two of those patients died within a year of their transplants; one was followed up 5 months after transplant and found to have essentially unchanged serum MBL. The other four patients were in complete remission at the time this report was being prepared. Fresh blood samples from those four patients and their donors were obtained more than 2 years after transplantation. Two of the donors had MBL concentrations p10 ng/ml. Both of their recipients had blood sampled at around 3 months post transplant and finally between 2 and 3 years after transplantation. Unsurprisingly, those samples all had MBL concentrations o100 ng/ ml, similar to the pre-transplant values.
The other two donors had relatively high MBL concentrations (above the median value of 1300 ng/ml for healthy adults); those donor-recipient pairs are described below.
Patient 1
This was a 42-year-old male with myeloma. He was treated with an HLA-matched sibling bone marrow transplant from his brother, aged 50 years. The transplant was uncomplicated and the patient remained in complete remission throughout the follow-up period. The donor's serum MBL concentration was 2100 ng/ml. The patient's blood was sampled a week before transplant, on the day of transplant, and at 2. 
Patient 2
This was a 45-year-old male with non-Hodgkin's lymphoma. He was treated with an HLA-matched unrelated donor mini-bone marrow transplant from a male donor aged 28 years. The transplant was uncomplicated and the patient remained in complete remission throughout the follow-up period. The donor's serum MBL concentration was 1500 ng/ml. The patient's blood was sampled a week before transplant, on the day of transplant, and at 2 weeks, 3, 3.5, 4 and finally 27 months post transplant. The MBL concentration at 2 weeks post transplant was 80 ng/ml; all the other samples had MBL p10 ng/ml. (The slightly raised value after 2 weeks post transplant was reproducible. Although a significant several-fold increase, the highest value is still very low and within the range expected of mutant structural gene homozygotes.) 
Discussion
This is the first study to investigate directly a change of MBL status from stem cell transplantation. We have reported two cases of allogeneic stem cell transplantation involving donors with high MBL concentrations and recipients with virtually undetectable MBL before transplantation. One patient had a sibling donor, the other had an unrelated donor selected from a bone marrow registry. In neither instance did the marrow donation result in an increase in circulating MBL in the recipient over a followup period of more than 2 years. We have therefore demonstrated that haemopoietic stem cell transplantation does not necessarily correct MBL deficiency.
A series of two is not exhaustive and does not rigorously exclude the possibility that MBL replacement may sometimes be achieved by leucocyte donation. Ideally, this analysis should be extended to a large number of donorrecipient pairs before definite conclusions can be drawn. Nevertheless, haemopoietic stem cell transplantation clearly does not guarantee MBL replacement after successful tissue engraftment, and the obvious preliminary conclusion is that the MBL genotype of the donor does not influence post transplant serum MBL levels in the recipient. These results do not provide an explanation for the findings of Mullighan et al 6 that donor (as well as recipient) MBL genotype was independently associated with infection in multivariate analysis. A curious aspect of that study was the finding that the association was actually stronger and much more significant with donor MBL status (OR 4.1, P ¼ 0.002, for donor genotype vs OR 2.6, P ¼ 0.04, for recipient genotype) than for recipient MBL status. That is inherently hard to explain, for even if extrahepatic synthesis could be tranferred in leucocytes, it is unclear how MBL replacement by that means could be more effective than natural MBL synthesis from a patient's liver. The relationship taken at face value would certainly require a very strong correlation between engraftment and correction of MBL deficiency, which seems unlikely in view of the results reported here.
However, it is possible that the donor MBL association is due to the influence of an unrelated gene on chromosome 10 in linkage disequilibrium with the mbl-2 gene, or that the donor MBL concentration prior to stem cell harvest can influence the immune repertoire of the donor and ultimately of the recipient. Our results indicate that such alternative explanations should be considered and investigated.
